Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TFUKJvM
via IFTTT

Read More

Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWZO8sX
via IFTTT

Read More

Fortis liability case: Delhi HC says blame can't be shifted to third party

Amid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the Singh brothers, former promoters of the company. The court's remarks suggest that Fortis had a responsibility to inhibit such transactions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r02xIH5
via IFTTT

Read More

Invisalign maker Align Technology to invest Rs 1,800 crore in Hyderabad plant

US firm Align Technology will invest Rs 1,800 crore in Hyderabad for its first Indian manufacturing plant. This facility will be the company's fourth globally. It is expected to create over 300 jobs. The investment will boost Align Technology's existing operations in the city. The new plant will support its worldwide production of clear aligners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BphLCdz
via IFTTT

Read More

Pregabalin moved to Schedule H1 as centre cracks down on drug misuse

Pregabalin, a nerve pain medication, now faces stricter controls. The Union health ministry has moved it to Schedule H1. This change aims to curb its misuse, especially among youth. Previously available over-the-counter, it now requires strict prescriptions. Pharmacies must maintain records and display prominent warnings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Si5YHum
via IFTTT

Read More

ICMR replaces old system with single window approval for medical studies

The Indian Council of Medical Research has introduced a unified ethics approval process for multicentre medical studies, replacing the previous fragmented, site-by-site system. This significant reform aims to expedite research timelines, reduce costs, and expand participation to rural and vulnerable populations, fostering more representative and robust health policy evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnMQj3G
via IFTTT

Read More

Eli Lilly’s obesity drug shows up to 30% weight loss in trial

Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple hormone receptors. The drug also improved heart health markers. Experts believe retatrutide could be a game-changer for treating obesity and improving patient health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FJEq4Sa
via IFTTT

Read More